Caloric restriction in women with the triple negative disease was found to reduce incidence of metastases in a pre-clinical model.
Dieting may decrease chances for metastases in triple negative breast cancers by strengthening the tissue surrounding the tumour.
Calorie restriction, a kind of dieting in which food intake is decreased by a certain percentage, has been touted as way to help people live longer. New research suggests that there may be other benefits, including improving outcomes for women in breast cancer.
According to a study published on 26 May in Breast Cancer Research and Treatment, the triple negative subtype of breast cancer — one of the most aggressive forms – is less likely to spread, or metastasize, to new sites in the body when mice were fed a restricted diet.
''The diet turned on a epigenetic program that protected mice from metastatic disease,'' says senior author Nicole Simone, M.D., an associate professor in the department of Radiation Oncology at Thomas Jefferson University.
Read the report here: http://bit.ly/1qJPn11
Source: domain-b.com
Pembrolizumab Receives Full Approval for Select Patients With MSI-H or dMMR Solid Tumors
March 29th 2023The FDA has granted full approval to pembrolizumab for the treatment of some patients with unresectable or metastatic microsatellite instability–high (MSI-H) or mismatch repair–deficient (dMMR) solid tumors that have progressed following previous treatment.
Read More
The FDA wants to discourage the use of single-arm trials for accelerated approvals of oncology drugs; Cigna’s review system allows doctors to reject claims without reading them, an investigation shows; US bishops want to restrict gender transition care in Catholic hospitals.
Read More
Lymphoma Research Foundation CEO on Biden’s Cancer Moonshot, Financial Toxicity
February 3rd 2022On this episode of Managed Care Cast, we speak with Meghan Gutierrez, CEO of the Lymphoma Research Foundation, about financial toxicity, how the pandemic has affected patients’ financial needs when they have cancer, health care disparities and care gaps, and more.
Listen
Osimertinib Demonstrates Overall Survival Benefit as Adjuvant Lung Cancer Treatment
March 19th 2023Osimertinib (Tagrisso; AstraZeneca) now has shown a statistically significant and clinically meaningful overall survival benefit in both the early adjuvant and late-stage metastatic settings.
Read More
2 Clarke Drive
Cranbury, NJ 08512